Lederle Laboratories

Vivoryon Therapeutics N.V. Announces Proposed Appointment of Dr. Frank Weber as Chief Executive Officer Frank Weber, MD, current Chief Medical Officer (CMO), promoted to Chief Executive Officer (CEO) to lead Company through next stage of development with focus on upcoming VIVIAD trial readout in 1Q24To-Date, varoglutamstat has demonstrated potential for meaningful safety and ease of use advantages over antibody-based therapies, continues to show encouraging safety data at therapeutic dose of 600 mg twice daily, a dose demonstrated to result in nearly 90% target occupancyAnne Doering, CFA, to assume newly created position of Chief Strategy & Investor Relations Officer (CS&IRO) to bolster continued efforts to support varoglutamstat and Vivoryon corporate goalsVivoryon to report first half 2023 financial results and operational progress on September 7, 2023 Halle (Saale) / Munich, Germany, August 4, 2023 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon, or the Company), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, announced that Frank Weber, MD, Vivoryon’s Chief Medical Officer (CMO) will assume current CEO Dr. Ulrich Dauer's responsibilities effective August 14, 2023. Dr. Weber has a long-standing history with the Company, having joined Vivoryon in 2010. He has deep knowledge of the scientific foundation of the Company and has been integral in shaping varoglutamstat’s rigorous clinical development strategy. Dr. Ulrich Dauer will support the Company through the transition period in an advisory role through the end of 2023. “I am honored to become the next CEO of Vivoryon and to continue to work alongside Uli and the team through this transition period. We have developed a truly differentiated and compelling small molecule for the treatment of Alzheimer’s disease, and I am excited to lead this team through varoglutamstat’s late clinical-stage development as we work tirelessly to bring this exceptional product to patients in need. I look forward to leading the Company through VIVIAD’s trial readout in the first quarter of 2024 as well as partnering with the broader management team and the Board to further support Vivoryon along its future growth path. Contrasted with currently approved products, varoglutamstat’s convenient oral administration and promising safety profile with no ARIAs has potential to be a transformative medicine that can deliver extraordinary value to patients with Alzheimer’s disease and their caregivers. As varoglutamstat approaches the final stages of its Phase 2 development, I feel confident that the Company is poised to become a leader in the field of Alzheimer’s disease treatment with our novel approach,” commented Frank Weber, MD. “I also would like to express my deep gratitude to Uli not only as the leader of Vivoryon for many years, but also as a trusted partner throughout my role as CMO.” Further management changes include Anne Doering, CFA, the Company's current Head of Investor Relations, taking on the newly created position of CS&IRO effective August 14, 2023, supporting Dr. Weber. Ms. Anne Doering joined Vivoryon as Head of Investor Relations in April 2023, focusing on expanding the Company’s investor communications and network by leveraging her capital markets experience. In this newly created position, Ms. Doering will lead the development and execution of portfolio and growth strategies for the Company while remaining responsible for investor relations activities. “Uli’s leadership has transformed Vivoryon to become a financially stable company with clinical and operational success. Vivoryon has never been stronger and is well-positioned for the future with a clear, differentiated strategy in Alzheimer’s disease and is at the cusp of delivering extraordinary value for patients and shareholders. It is with great pleasure that we announce Frank’s designation as CEO. The Board has worked closely with Frank for several years and we believe that he will be a significant asset to the company in this new role, having been a true partner in all aspects of Vivoryon’s business in a leadership capacity. Given Frank’s extensive clinical development expertise and his integral role in varoglutamstat’s clinical development strategy, combined with his corporate strategy and financial experience resulting from numerous successful transactions throughout his tenure, we feel he is the natural choice to succeed Uli. We have full confidence that he will successfully steer Vivoryon as we approach a clinical inflection point with our upcoming VIVIAD results in the first quarter of 2024 and we anticipate a smooth and effective leadership transition,” commented Dr. Erich Platzer, Chairman of the Board. “In addition, Anne’s experience complements the new leadership team very well, broadening the Company’s visibility in the capital markets and supporting Frank through key inflection points with varoglutamstat. We welcome her on board.” Dr. Weber brings 30 years of experience in the pharmaceutical and life science industry. He supported InterMune (now Genentech/Roche), in particular, its launch of Esbriet in Europe, as Global Clinical Advisor. Prior to this, he served as Chief Medical Officer at Merck KGaA in Germany and Switzerland, where he contributed to several marketing authorizations and market access agreements in the EU, U.S. and Japan and also spearheaded personalized medicine, biomarker and companion diagnostics. During his career, he has also been involved in several M&A transactions as well as licensing deals. Dr. Weber started his industry career after ten years in academic clinical research and patient care in the areas of cancer, immunology, infectiology and maxillo-facial surgery. His past roles include management positions in medical affairs and clinical development at American Cyanamid (Lederle), USA and at Synthelabo (now Sanofi), France. Dr. Weber is also a board member at Zambon Biotech SA, a Swiss-based private company searching for innovative in-licensing projects for the Zambon Group. Dr. Weber is a licensed physician and received his MD in Cancer Immunology from the Medical University Cologne, Germany. Ms. Doering brings over 25 years of capital markets, investment and corporate biopharmaceutical industry experience. Prior to joining Vivoryon, Ms. Doering was Director of Investor Relations at BioNTech and Director of Group Strategy at Merck KGaA, where she contributed to the strategic direction of the company. Her additional corporate experience includes R&D finance and strategy at Merck & Co. On the investment front, Ms. Doering helped build the Franklin European Equity Funds franchise at Franklin Templeton, a leading global asset manager, as portfolio manager and analyst and has spent time in venture capital at Creathor Ventures in Germany. In addition, for several years Ms. Doering was a healthcare equity research analyst covering pharmaceutical companies for a number of investment banks in New York including Bear Stearns, Credit Suisse, Bank of America and Commerzbank, during which time she was instrumental in the team achieving a #1 Institutional Investor ranking. Ms. Doering holds an MBA from The Wharton School and an MA in International Studies from The Lauder Institute, both of the University of Pennsylvania. She is also a Chartered Financial Analyst (CFA) Charterholder. Vivoryon will hold an Extraordinary General Meeting (EGM) on Friday, September 15, 2023, in connection with the appointment of Dr. Weber and Ms. Doering to the Company’s Board as executive directors ### About Vivoryon Therapeutics N.V.Vivoryon is a clinical stage biotechnology company focused on developing innovative small molecule-based medicines. Driven by our passion for ground-breaking science and innovation, we strive to change the lives of patients in need suffering from severe diseases. We leverage our in-depth expertise in understanding post-translational modifications to develop medicines that modulate the activity and stability of proteins which are altered in disease settings. Beyond our lead program, varoglutamstat, which is in Phase 2 clinical development to treat Alzheimer’s disease, we have established a solid pipeline of orally available small molecule inhibitors for various indications including cancer, inflammatory diseases and fibrosis. www.vivoryon.com Vivoryon Forward Looking StatementsThis press release includes forward-looking statements, including, without limitation, those regarding the business strategy, management plans and objectives for future operations of the Vivoryon Therapeutics N.V. (the “Company”), estimates and projections with respect to the market for the Company’s products and forecasts and statements as to when the Company’s products may be available. Words such as “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “project,” “predict,” “should” and “will” and similar expressions as they relate to the Company are intended to identify such forward-looking statements. These forward-looking statements are not guarantees of future performance; rather they are based on the Management’s current expectations and assumptions about future events and trends, the economy and other future conditions. The forward-looking statements involve a number of known and unknown risks and uncertainties. These risks and uncertainties and other factors could materially adversely affect the outcome and financial effects of the plans and events described herein. Actual results, performance or events may differ materially from those expressed or implied in such forward-looking statements and from expectations. As a result, no undue reliance should be placed on such forward-looking statements. This press release does not contain risk factors. Certain risk factors that may affect the Company’s future financial results are discussed in the published annual financial statements of the Company. This press release, including any forward-looking statements, speaks only as of the date of this press release. The Company does not assume any obligation to update any information or forward-looking statements contained herein, save for any information required to be disclosed by law. This press release contains inside information within the meaning of Regulation (EU) No 596/2014. For more information, please contact: Investor ContactStern IRJulie SeidelTel: +1 212-698-8684Email: SternIR-Vivoryon@sternir.com Media ContactTrophic CommunicationsValeria FisherTel: +49 175 8041816Email: vivoryon@trophic.eu Attachment 20230804_Announces Proposed Appointment of Dr. Frank Weber as Chief Executive Officer

-- New Financing of $24 Million Fully Funds the Phase 2 Clinical Program for Lead Candidate VLX-1005 -- Company Prepares to Evaluate VLX-1005 in Heparin-Induced Thrombocytopenia (HIT) FREDERICK, Md., June 20, 2023 (GLOBE NEWSWIRE) -- Veralox Therapeutics, a clinical-stage biotechnology company developing a new class of therapies targeting the 12-lipoxygenase (12-LOX) pathway to address some of medicine’s most persistent and serious immune-mediated diseases, today announced the appointment of Jonathan Mow as the company’s new chief executive officer. Mr. Mow’s appointment comes as Veralox secured $24 million in funding to advance VLX-1005 through a Phase 2a proof-of-concept study evaluating its impact on heparin-induced thromobcytopenia (HIT), a life-threatening rare disease caused by an aberrant immune response to heparin exposure. The investment round included new investors Pappas Capital and NYBC Ventures and existing investors Hatteras Venture Partners, Sanofi Ventures, JDRF T1D Fund and Genesys Capital, amongst others. In conjunction with the financing, the company welcomes Peter Young of Pappas Capital as a director and Meg Wood of NYBC Ventures as an observer. “VLX-1005 has great promise to revolutionize the treatment of HIT and other immune-mediated diseases,” Mr. Young said. “I am thrilled to join the board at such an exciting time, and to be working with a leader of Jonathan’s caliber to move into later stages of clinical development.” “This is an exciting time for Veralox as we head into our proof-of-concept Phase 2 study with VLX-1005 for HIT, a serious complication subsequent to heparin exposure that is accompanied by significant morbidity and mortality,” Mr. Mow said. “Our novel approach with 12-LOX inhibitors has great potential in this and other diseases and I would like to thank our investors for their financial support of our important mission and giving me the opportunity to lead this world-class effort and team.” Mr. Mow brings more than 25 years of accomplishments in biotechnology management to Veralox, most recently serving as CEO of PhaseBio Pharmaceuticals. At PhaseBio, he led the company’s scientific and business transformations, guiding the company from early-stage research to Phase 3 development, and through a successful initial public offering in 2018. Earlier in his career, Mr. Mow served as vice president, business development for Amylin Pharmaceuticals until its sale to Bristol-Myers Squibb in 2012; was co-founder and vice president, commercial and business development of Corus Pharma, Inc. until its acquisition by Gilead Sciences in 2006; and headed business development for PathoGenesis Corporation until its acquisition by Chiron Corporation in 2000. Mr. Mow has also held positions in marketing, marketing research and sales at Bristol-Myers Squibb, Wyeth/Lederle International and Syntex Laboratories. He holds a B.S. in mechanical engineering from University of California at Berkeley and M.B.A. from Carnegie Mellon University’s Tepper School of Business. About Veralox TherapeuticsVeralox Therapeutics Inc. is the clinical leader in developing first-in-class therapeutics targeting 12-lipoxygenase, pioneering a new class of therapies that treat the underlying pathologies of serious immune-inflammatory diseases with unmet medical needs. The company’s lead candidate, VLX-1005, is in development for the treatment of patients with heparin-induced thrombocytopenia (HIT). VLX-1005 has orphan drug designation in the United States and has been awarded Fast Track Designation by the U.S. Food and Drug Administration. Second generation therapeutic products are under development for type 1 diabetes and other immune-mediated and inflammatory diseases. For more information, visit our website: https://veralox.com/. Media Contact: Lisa GuitermanScient PR202-330-3431Lisa.guiterman@gmail.com

BOCA RATON, Fla. & SARASOTA, Fla.--(BUSINESS WIRE)-- Akron Biotech (“Akron”), a provider of critical inputs for cell and gene therapies, today announced the appointment of Christopher Murphy as Chief Executive Officer. Akron is a portfolio company of Arcline Investment Management. Mr. Murphy is a biotechnology industry veteran with more than 30 years of experience in advanced therapy and biological drug development and manufacturing. Most recently, he served as Vice President and General Manager of Viral Vector Services at Thermo Fisher Scientific. Mr. Murphy joined Thermo Fisher Scientific as part of its acquisition of Brammer Bio, where he served as Chief Operations Officer. Previously, he held leadership roles at Sanofi Genzyme, BioReliance, and Lederle Laboratories (now Pfizer). Arcline commented, “Chris brings an exceptional track record of building and growing businesses that address critical demands in the rapidly developing cell and gene therapy industry. We are thrilled to welcome Chris as Akron’s CEO and believe his passion and expertise will be invaluable in strengthening the company’s position as a leading supplier to cell and gene therapy companies.” Mr. Murphy said, “I am incredibly excited to join Akron Bio and partner with innovators to provide high-quality, critical materials and services that power the future of medicine. Our differentiated products, expertise, and agility are crucial in this rapidly evolving advanced therapy industry. I look forward to working with this exceptional team to enable customers to realize the potential of these medicines for people in need.” About Akron Bio Akron Bio is a leading materials manufacturer and services provider to the regenerative medicine industry. Akron Bio leverages more than 100,000 square feet of development and manufacturing capacity to provide advanced therapy developers the scale, compliance and regulatory support necessary to drive novel treatments from discovery to commercialization. For more information, please visit .